200 related articles for article (PubMed ID: 26551082)
1. CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer.
Olsen J; Eiholm S; Kirkeby LT; Espersen ML; Jess P; Gögenür I; Olsen J; Troelsen JT
Exp Mol Pathol; 2016 Feb; 100(1):59-66. PubMed ID: 26551082
[TBL] [Abstract][Full Text] [Related]
2. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
3. Assessment of mismatch repair deficiency, CDX2, beta-catenin and E-cadherin expression in colon cancer: molecular characteristics and impact on prognosis and survival - an immunohistochemical study.
Melincovici CS; Boşca AB; Şuşman S; Cutaş A; Mărginean M; Ilea A; Moldovan IM; Jianu EM; Neag MA; Bulboacă AE; Mihu CM
Rom J Morphol Embryol; 2020; 61(3):715-727. PubMed ID: 33817713
[TBL] [Abstract][Full Text] [Related]
4. The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review.
Olsen J; Espersen ML; Jess P; Kirkeby LT; Troelsen JT
Surg Oncol; 2014 Sep; 23(3):167-76. PubMed ID: 25126956
[TBL] [Abstract][Full Text] [Related]
5. Tumor and Patient Characteristics of Individuals with Mismatch Repair Deficient Colorectal Cancer.
Waldmann E; Ferlitsch M; Binder N; Sellner F; Karner J; Heinisch B; Klimpfinger M; Trauner M
Digestion; 2015; 91(4):286-93. PubMed ID: 25924923
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor-1alpha modulates the down-regulation of the homeodomain protein CDX2 in colorectal cancer.
Zheng J; Sun X; Wang W; Lu S
Oncol Rep; 2010 Jul; 24(1):97-104. PubMed ID: 20514449
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage.
Ye J; Zhou Y; Weiser MR; Gönen M; Zhang L; Samdani T; Bacares R; DeLair D; Ivelja S; Vakiani E; Klimstra DS; Soslow RA; Shia J
Hum Pathol; 2014 Dec; 45(12):2430-6. PubMed ID: 25311944
[TBL] [Abstract][Full Text] [Related]
8. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
[TBL] [Abstract][Full Text] [Related]
9. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
[TBL] [Abstract][Full Text] [Related]
11. Expression and localisation of insulin receptor substrate 2 in normal intestine and colorectal tumours. Regulation by intestine-specific transcription factor CDX2.
Modica S; Morgano A; Salvatore L; Petruzzelli M; Vanier MT; Valanzano R; Esposito DL; Palasciano G; Duluc I; Freund JN; Mariani-Costantini R; Moschetta A
Gut; 2009 Sep; 58(9):1250-9. PubMed ID: 19221108
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.
Bodo S; Colas C; Buhard O; Collura A; Tinat J; Lavoine N; Guilloux A; Chalastanis A; Lafitte P; Coulet F; Buisine MP; Ilencikova D; Ruiz-Ponte C; Kinzel M; Grandjouan S; Brems H; Lejeune S; Blanché H; Wang Q; Caron O; Cabaret O; Svrcek M; Vidaud D; Parfait B; Verloes A; Knappe UJ; Soubrier F; Mortemousque I; Leis A; Auclair-Perrossier J; Frébourg T; Fléjou JF; Entz-Werle N; Leclerc J; Malka D; Cohen-Haguenauer O; Goldberg Y; Gerdes AM; Fedhila F; Mathieu-Dramard M; Hamelin R; Wafaa B; Gauthier-Villars M; Bourdeaut F; Sheridan E; Vasen H; Brugières L; Wimmer K; Muleris M; Duval A;
Gastroenterology; 2015 Oct; 149(4):1017-29.e3. PubMed ID: 26116798
[TBL] [Abstract][Full Text] [Related]
13. Pitfalls in molecular analysis for mismatch repair deficiency in a family with biallelic pms2 germline mutations.
Leenen CH; Geurts-Giele WR; Dubbink HJ; Reddingius R; van den Ouweland AM; Tops CM; van de Klift HM; Kuipers EJ; van Leerdam ME; Dinjens WN; Wagner A
Clin Genet; 2011 Dec; 80(6):558-65. PubMed ID: 21204794
[TBL] [Abstract][Full Text] [Related]
14. The Significance of Mismatch Repair Deficiency in Young Patients With Endometrial Cancer.
Chu MM; Liu SS; Tam KF; Ip PP; Cheung AN; Ngan HY
Int J Gynecol Pathol; 2015 Sep; 34(5):403-10. PubMed ID: 26262451
[TBL] [Abstract][Full Text] [Related]
15. Cdx2 controls expression of the protocadherin Mucdhl, an inhibitor of growth and β-catenin activity in colon cancer cells.
Hinkel I; Duluc I; Martin E; Guenot D; Freund JN; Gross I
Gastroenterology; 2012 Apr; 142(4):875-885.e3. PubMed ID: 22202456
[TBL] [Abstract][Full Text] [Related]
16. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
17. Involvement of CDX2 in the cross talk between TNF-α and Wnt signaling pathway in the colon cancer cell line Caco-2.
Coskun M; Olsen AK; Bzorek M; Holck S; Engel UH; Nielsen OH; Troelsen JT
Carcinogenesis; 2014 May; 35(5):1185-92. PubMed ID: 24501326
[TBL] [Abstract][Full Text] [Related]
18. Relationship among mismatch repair deficiency, CDX2 loss, p53 and E-cadherin in colon carcinoma and suitability of using a double panel of mismatch repair proteins by immunohistochemistry.
Sayar I; Akbas EM; Isik A; Gokce A; Peker K; Demirtas L; Gürbüzel M
Pol J Pathol; 2015 Sep; 66(3):246-53. PubMed ID: 26619103
[TBL] [Abstract][Full Text] [Related]
19. CDX2 Protein Expression in Colorectal Cancer and ItsCorrelation with Clinical and Pathological Characteristics, Prognosis, and Survival Rate of Patients.
Asgari-Karchekani S; Karimian M; Mazoochi T; Taheri MA; Khamehchian T
J Gastrointest Cancer; 2020 Sep; 51(3):844-849. PubMed ID: 31630373
[TBL] [Abstract][Full Text] [Related]
20. Expression of homeodomain protein CDX2 in colorectal adenoma and adenocarcinoma.
Bakaris S; Cetinkaya A; Ezberci F; Ekerbicer H
Histol Histopathol; 2008 Sep; 23(9):1043-7. PubMed ID: 18581275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]